The Astellas Group has established a management structure as described below.
Top Management (as of June 2023)
In order to build an optimal management system capable of agile and appropriate decision making, Astellas maintains a global organizational structure covering the entire Group across nearly all of its divisions including those of Research, Development, Manufacturing, and administrative functions, and appoints Top Management to take charge of such activities. Top management consists of the Representative Director, President and CEO and members who are in charge of each business area.
 |
Naoki Okamura Representative Director, President and Chief Executive Officer (CEO) |
Division in charge
Digital, Analytics & Technology, External Relations, Healthcare Policy, Internal Audit, Quality Assurance, Sustainability, CFO Office, Corporate Accounting & Global Business Services, Corporate Communications, Corporate Finance & Control, Procurement, Treasury & TaxClose
 |
Katsuyoshi Sugita Representative Director, Executive Vice President, Chief People Officer and Chief Ethics & Compliance Officer (CPO & CECO) |
Division in charge
Ethics & Compliance, Human ResourcesClose
 |
Yoshitsugu Shitaka, Ph.D. Chief Scientific Officer (CScO) |
Division in charge
Affiliate Engagement, Applied Research & Operations, Discovery Accelerator, Gene Therapy Research & Technical Operations, Immuno-Oncology, Institute for Regenerative Medicine, Mitobridge, Research Strategy & Communications, Targeted Protein Degradation, Universal Cells, Xyphos BiosciencesClose
 |
Tadaaki Taniguchi, M.D., Ph.D. Chief Medical Officer (CMO) |
Division in charge
Biopharma Development, Cell and Gene Therapy Development, Clinical Operations, Data Science, Development Project Management, Early Development, Immuno-Oncology Development, Medical Affairs, M&D Strategy & Operations, Oncology Development, Pharmacovigilance, Regulatory AffairsClose
 |
Hideki Shima Chief Manufacturing Officer (CMfgO) |
Division in charge
BioPharma Manufacturing, CMC Development, CMC Product Management, CMC Research, CMfgO Office, Pharma Manufacturing, Supply Chain Management, Technology & Manufacturing Capability and ComplianceClose
 |
Claus Zieler Chief Commercial Officer (CCO) |
Division in charge
Established Markets Commercial, Gene Therapy Commercial, Greater China Commercial, International Markets Commercial, Japan Commercial, United States Commercial, Commercial Capabilities, Commercial Strategy, Market Access & Pricing, Strategic Brand Marketing Medical Specialties, Strategic Brand Marketing OncologyClose
 |
Adam Pearson Chief Strategy Officer (CStO) |
Division in charge
Business Development, Corporate Strategy, iota Biosciences, Patient Centricity, Primary Focus Lead Blindness & Beyond, Primary Focus Lead Genetic Regulation, Primary Focus Lead Immune Homeostasis, Primary Focus Lead Immuno-Oncology, Primary Focus Lead Mitochondria, Primary Focus Lead Targeted Protein Degradation, Rx+ Business Accelerator, Transformation OfficeClose
 |
Catherine Levitt General Counsel (GC) |
Division in charge
LegalClose
Executive Committee (as of June 2023)
Astellas has the Executive Committee, chaired by the Representative Director, President and CEO, as a body for discussion on important matters in global management of the Astellas Group. Members consist of Top Management.
Members
| Representative Director, President and Chief Executive Officer (CEO) |
Naoki Okamura |
| Representative Director, Executive Vice President, Chief People Officer and Chief Ethics & Compliance Officer (CPO & CECO) |
Katsuyoshi Sugita |
| Chief Scientific Officer (CScO) | Yoshitsugu Shitaka, Ph.D. |
| Chief Medical Officer (CMO) | Tadaaki Taniguchi, M.D., Ph.D. |
| Chief Manufacturing Officer (CMfgO) | Hideki Shima |
| Chief Commercial Officer (CCO) | Claus Zieler |
| Chief Strategy Officer (CStO) | Adam Pearson |
| General Counsel (GC) | Catherine Levitt |
※Naoki Okamura, Representative Director, President and Chief Executive Officer (CEO), concurrently holds the position of Chief Financial Officer(CFO).